Regorafenib vs placebo for Refractory Advanced Gastric Cancer, summarised by Erman Akkus
Erman Akkus shared a post on X:
“Regorafenib vs placebo for Refractory Advanced Gastric Cancer
INTEGRATE Journal of Clinical Oncology
At least 2 lines of previous therapy for advanced disease
Median OS: 4.5 vs 4 mo
HR: 0.70 (0.56 to 0.87) P = .001
12-month survival rates: 19% vs 6%
mPFS: 1.8 vs 1.6 mo
HR: 0.53 [0.40 to 0.70] P < .0001
delayed deterioration in global QoL
Although statistically significant, clincially not significant benefit Use in 1st and 2nd line?
Phase 2 First-line regorafenib with nivolumab and chemotherapy >can be safely combined
Phase III trials planned.”
INTEGRATE IIa Phase III Study: Regorafenib for Refractory Advanced Gastric Cancer
Authors: Nick Pavlakis, et al.
Source: Erman Akkus/X
Erman Akkus is a medical oncology fellow at the Ankara University, Faculty of Medicine. Previously, he was an Internal Medicine Resident at the Ankara University, Faculty of Medicine. He was also a Visiting Researcher at the University of Oslo. He completed his education from the Medical University of Vienna.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023